| scholarly article | Q13442814 |
| P50 | author | Rajiv Kumar | Q89337278 |
| Michael P. Whyte | Q89919619 | ||
| Steven Mumm | Q95336496 | ||
| P2093 | author name string | Fan Zhang | |
| Deborah Wenkert | |||
| Theresa J Berndt | |||
| P2860 | cites work | Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent | Q24319643 |
| Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy | Q24657630 | ||
| Research Progress in Pseudoxanthoma Elasticum and Related Ectopic Mineralization Disorders | Q26827073 | ||
| Asfotase alfa therapy for children with hypophosphatasia | Q27334025 | ||
| Marrow cell transplantation for infantile hypophosphatasia | Q28188482 | ||
| Hypophosphatasia | Q28214046 | ||
| New perspectives on the biology and treatment of X-linked hypophosphatemic rickets | Q28236776 | ||
| Hypophosphatasia; a new developmental anomaly | Q28262191 | ||
| Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients | Q28269711 | ||
| Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets | Q33645895 | ||
| Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone | Q34060286 | ||
| Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum | Q34421007 | ||
| Markedly increased circulating pyridoxal-5'-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism | Q34549377 | ||
| X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy | Q35436986 | ||
| Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects | Q36470066 | ||
| Alkaline Phosphatase and Hypophosphatasia | Q36778063 | ||
| An integrated understanding of the physiological response to elevated extracellular phosphate. | Q36986316 | ||
| Hypophosphatemia: the common denominator of all rickets | Q37510688 | ||
| The expanding family of hypophosphatemic syndromes | Q37968185 | ||
| Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment | Q38740282 | ||
| Hypophosphatasia: Natural history study of 101 affected children investigated at one research center | Q39439713 | ||
| A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum | Q39760099 | ||
| Adult hypophosphatasia. Clinical, laboratory, and genetic investigation of a large kindred with review of the literature | Q39961547 | ||
| Biological activity of FGF-23 fragments | Q40164192 | ||
| Adult hypophosphatasia with chondrocalcinosis and arthropathy. Variable penetrance of hypophosphatasemia in a large Oklahoma kindred | Q40340161 | ||
| Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors | Q40488393 | ||
| MEPE has the properties of an osteoblastic phosphatonin and minhibin. | Q40590136 | ||
| Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients | Q41321464 | ||
| Infantile hypophosphatasia: autosomal recessive transmission to two related sibships | Q41834162 | ||
| Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schönberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders | Q43055107 | ||
| Absence of significant secretory flux of phosphate in the proximal convoluted tubule | Q44383389 | ||
| Hypophosphatasia: a developmental anomaly of alkaline phosphatase? | Q44615016 | ||
| EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA. | Q46288486 | ||
| Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders | Q46936767 | ||
| Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy | Q48379638 | ||
| PHEX 3'-UTR c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets. | Q51318721 | ||
| Enzyme-replacement therapy in life-threatening hypophosphatasia. | Q51806696 | ||
| Hypophosphatasia: molecular diagnosis of Rathbun's original case. | Q52129845 | ||
| Hypophosphatasia: Biochemical hallmarks validate the expanded pediatric clinical nosology. | Q52735239 | ||
| Burosumab Therapy in Children with X-Linked Hypophosphatemia | Q59701850 | ||
| On the correlation between alkaline phosphatase and phosphate transport in rat renal brush border membrane vesicles. | Q64889447 | ||
| Phosphorylethanolamine and hypophosphatasia | Q68593373 | ||
| Studies on rabbit kidney brush border membranes: relationship between phosphate transport, alkaline phosphatase and NAD | Q70043161 | ||
| Renal transport of phosphate: role of alkaline phosphatase | Q70789204 | ||
| Fifty-year follow-up of hypophosphatasia | Q70995237 | ||
| Selective removal of alkaline phosphatase from renal brush-border membrane and sodium-dependent brush-border membrane transport | Q71741198 | ||
| [A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics] | Q73829329 | ||
| EFFECT OF ORTHOPHOSPHATE ON URINARY PYROPHOSPHATE EXCRETION AND THE PREVENTION OF UROLITHIASIS | Q76773486 | ||
| URINARY PYROPHOSPHATE AND UROLITHIASIS | Q76819485 | ||
| Adult hypophosphatasia treated with teriparatide | Q79527711 | ||
| Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement | Q81038213 | ||
| Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23 | Q86598312 | ||
| Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum | Q88006122 | ||
| Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial | Q90592978 | ||
| Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia | Q90702710 | ||
| Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial | Q91027821 | ||
| Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations | Q91883529 | ||
| X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study) | Q92472500 | ||
| Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study | Q93063587 | ||
| P921 | main subject | hypophosphatasia | Q1313510 |
| P304 | page(s) | 115300 | |
| P577 | publication date | 2020-02-26 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia | |
| P478 | volume | 134 |
Search more.